While this current SLR focused on the impact of surgery and lifestyle modifications on cancer risk reduction, with the recent approval of obesity management medications, including dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 (GIP/GLP‐1) receptor agonist (RA), there is a growing interest to explore their potential benefits on cancer prevention associated with weight reduction. Here, GIP is linked to obesity due to melanocortin 4 receptor deficiency.